Market Overview

UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

Related ABT
Benzinga Weekly Preview: Earnings Season Kicks Into High Gear
Morgan Stanley Issues 2015 'Vintage Values' Stock List
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

Stifel Nicolaus initiated Abbott Laboratories (NYSE: ABT) with a Buy rating and a $40.00 price target.

Stifel Nicolaus commented, "Post-spin, we believe Abbott is now a balanced, diversified medical products company with an attractive, long-term outlook for mid-to-upper single-digit sales growth and low double-digit EPS growth. Although ABT currently trades at a premium to its peers, we see potential for further EPS upside over time, driven by an intensified focus on growth and margin enhancing initiatives. Using a sum-of-the-parts valuation framework, we arrive at a $40 target price."

Abbott Laboratories closed at $34.46 on Thursday.

Posted-In: Stifel NicolausAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free